Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Stimuvax (L-BLP25 liposome vaccine) in multiple myeloma
2006-001810-33Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2007
- Modality
- Vaccines & Immunotherapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of tecemotide in multiple myeloma (MM), sponsored by Merck KGaA. Primary endpoint: Anti-MUC1 T-cell response. Started Aug 2007; status: completed.
02
Drugs
tecemotide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-001810-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001810-33.